“…Considering the remarkable heterogeneity of PCa, its molecular complexity, and its multifactorial nature, the incorporation of clinically valuable prognostic and predictive biomarker stratification for appropriate patient selection is potentially amenable in this process. In addition, the management of PCa is beginning to embrace the precision medicine approach with the use of new technologies, such as liquid tumor profiling, non-coding RNA diagnostics, genomic and proteomic analysis, gene editing, array-based technologies, and next-generation sequencing [ 2 , 3 , 33 ].…”